Astra

AZ, PTC collaborate in oncology

Thursday, June 30, 2011 09:59 AM

AstraZeneca and PTC Therapeutics are joining forces for cancer cures, using PTC's discovery/development technology platform, reported FierceBiotech.  AZ will front an undisclosed amount of cash to work on the first oncology target.

More... »

AstraZeneca could be eyeing Cubist

Monday, May 23, 2011 02:16 PM

Speculation late last week suggested AstraZeneca could be eyeing an acquisition of Cubist Pharmaceuticals, according to a report in The Telegraph.

More... »

Bayer CEO considers merger only if stars are aligned

Thursday, May 5, 2011 12:40 PM

German-based Bayer is open to a “merger of equals” that would enhance its health-care unit without paying a premium for an acquisition, says Bayer’s chief executive officer Marijn Dekkers, according to a Bloomberg report.

More... »

AstraZeneca will demolish research labs in Delaware

Monday, April 25, 2011 01:30 PM

AstraZeneca will tear down three research laboratory buildings at its headquarters in Fairfax, Delaware, as part of its global restructuring, according to delaware online.

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »

AstraZeneca's vandetanib approved for MTC

Thursday, April 7, 2011 11:35 AM

The FDA has approved AstraZeneca’s vandetanib, which is a kinase inhibitor and has no brand name yet, to treat adult patients with late-stage medullary thyroid cancer (MTC) who are ineligible for surgery and who have disease that is growing or causing symptoms. The once-daily oral treatment is the first agency-approved drug for MTC, which is estimated to represent 3%-5% of all thyroid cancer.

More... »

Neuroscience drug development slows, requires funding

Tuesday, March 29, 2011 11:49 AM

Many European pharmaceutical companies have significantly reduced their workflow in the realm of neuroscience, according to Fierce Biotech. Companies are challenged with a high risk of trial failure while investors demand new products. 

More... »

AstraZeneca drug enters phase III

Friday, March 18, 2011 10:28 AM

AstraZeneca has begun enrollment of a late-stage trial for an investigational opioid-induced constipation treatment licensed from Nektar Therapeutics.

More... »

AstraZeneca joins quest for TB therapies

Monday, March 7, 2011 10:43 AM

AstraZeneca became the newest member of a $22 million multi-member partnership to find new therapies for tuberculosis. The current remedies for the disease have been in use for over 50 years, and require several months or years of treatment. But with the expertise and help of companies including AZ and Sanofi-aventis, and academic partners University of Cambridge and institutions in Pavia, Italy and Uppsala, Sweden, the group hopes to cut treatment time.

More... »